Direct Relief, the National Association of Free and Charitable
Clinics (NAFC), and Teva Pharmaceuticals today launched a new
program to expand medication access and provide grant funding to
free and charitable clinics that care for medically underserved
patients suffering from depression and/or anxiety. Teva is
providing free and charitable clinics with $2 million in grant
funding over two years and making available, on a charitable basis,
a portfolio of commonly used generic medications that treat
depression and anxiety. The new pilot program – initially set in
Florida, New Jersey and California – aims to advance access to
mental health care for uninsured populations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220608005112/en/
"Access to mental health care is critical yet distributed
unevenly across the U.S.," said Thomas Tighe, CEO and President of
Direct Relief. "Direct Relief is joining NAFC and Teva
Pharmaceuticals in supporting community-based facilities to extend
mental health care for those most in need."
The COVID-19 pandemic exacerbated access to adequate health
services and mental health care needs. The new initiative will help
address mental health access through a two-pronged approach to
care: medication donations and community grants for free and
charitable clinics, to help address key equity issues and advance
quality care for underserved populations.
Products will be available to free and charitable clinics and
pharmacies in Direct Relief's network. NAFC will help identify and
evaluate programs eligible for grants and facilitate a community of
learning between grantee clinics.
"Free and Charitable Clinics are beacons in their communities
where access to affordable prescription medications and flexible
funding resources are obstacles faced every day," said Nicole
Lamoureux, President and CEO of NAFC. "With this program, we hope
to reduce barriers to care for underserved populations by working
with grantees to identify innovative, scalable ideas and approaches
that enhance mental and behavioral health care access, particularly
as the pandemic continues to spotlight severe inequities in
care."
Expanding Access and Delivering Care
Anxiety and depression disorders affect more than 40 million
adults in the U.S. every year.
Additionally, 84 percent of physicians reported an increase in new
diagnoses of mental health conditions since the pandemic began,
especially among racial and ethnic minorities and lower-income
households, according to a recent nationwide survey by the
Morehouse School of Medicine and Teva.
"As a company responsible for 1 in 12 generic prescriptions in
the U.S. with our portfolio of accessible medicines, it is critical
to our mission to help increase access to quality care," added Dr.
Sven Dethlefs, Executive Vice President, North America Commercial,
at Teva. "Through this partnership with Direct Relief and NAFC, we
are committed to reducing the disparities in health care that are
hindering health equity by uncovering novel solutions that improve
the lives of patients, their families and their communities."
Teva's support for the U.S. Access program stems from its public
commitment to launch eight global access programs by 2025. In 2020,
the company's generic medicines directly saved U.S. patients an
estimated $4.2 billion.
Grant Funding for Critical Facilities
As of today, Direct Relief will accept proposals from eligible
free and charitable clinics and charitable pharmacies, who are
members of the National Association of Free and Charitable
Clinics, in California, Florida, and New Jersey.
Specifically, Direct Relief seeks innovative programs that advance
health equity for populations with high unmet needs, support
patient education and outreach, service delivery, or point of care
models to help promote access or reduce barriers to care. Proposals
must address clinical or non-clinical interventions for treating
depression and anxiety for populations, including racial and ethnic
minorities and LGBTQIA+ individuals. Eligible clinics will be
contacted directly by Direct Relief.
About Direct Relief
A humanitarian organization committed to improving the health
and lives of people affected by poverty and emergencies, Direct
Relief delivers lifesaving medical resources throughout the U.S.
and world to communities in need—without regard to politics,
religion, or ability to pay. For more information, visit
https://www.DirectRelief.org.
About National Association of Free and Charitable
Clinics
National Association of Free and Charitable Clinics (NAFC) is
the only nonprofit 501c (3) organization whose mission is solely
focused on the issues and needs of the medically underserved
throughout the nation and the more than 1,400 Free and Charitable
Clinics that serve them. The NAFC has earned the Platinum Seal of
Transparency from GuideStar and a 4-star rating from Charity
Navigator. Founded in 2001 and headquartered near Washington, D.C.,
the NAFC is working to ensure that the medically underserved have
access to affordable quality health care and strives to be a
national voice promoting quality health care for all. For more
information about the NAFC, please visit www.nafcclinics.org.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic,
biosimilar and specialty medicines with a portfolio consisting of
over 3,500 products in nearly every therapeutic area. Around 200
million people around the world take a Teva medicine every day, and
are served by one of the largest and most complex supply chains in
the pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on Teva’s management current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to impact and
effectively execute on our social, economic, environment and
governance related strategies and goals; our ability to satisfy the
targets set forth in our sustainability-linked senior notes and in
other sustainability-linked financing instruments that we may
issue; and the impact of ESG issues on our business; our ability to
successfully compete in the marketplace, including: that we are
substantially dependent on our generic products; our substantial
indebtedness; our business and operations in general, including:
uncertainty regarding the COVID-19 pandemic and the governmental
and societal responses thereto, costs and delays resulting from the
extensive pharmaceutical regulation to which we are subject or
delays in governmental processing time due to travel and work
restrictions caused by the COVID-19 pandemic, the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; compliance, regulatory and
litigation matters, including: failure to comply with complex legal
and regulatory environments, increased legal and regulatory action
in connection with public concern over the abuse of opioid
medications and our ability to reach a final resolution of the
remaining opioid-related litigation; scrutiny from competition and
pricing authorities around the world, including our ability to
successfully defend against the U.S. Department of Justice criminal
charges of Sherman Act violations; potential liability for patent
infringement; product liability claims; failure to comply with
complex Medicare and Medicaid reporting and payment obligations;
and compliance with anti-corruption sanctions and trade control
laws; other financial and economic risks; and other factors
discussed in our Quarterly Report on Form 10-Q for the first
quarter of 2022 and in our Annual Report on Form 10-K for the year
ended December 31, 2021, including in the sections captioned “Risk
Factors” and “Forward-Looking Statements” and in our other reports
that we file with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220608005112/en/
For More Information: Direct Relief: Tony Morain –
TMorain@directrelief.org NAFC: Kerry Thompson –
kerry@nafcclinics.org Teva: Yonatan Beker –
Yonatan.Beker@tevapharm.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024